Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Analysis of data over 56 weeks shows that efficacy responses are maintained with upadacitinib 15 mg and 30 mg.
Following the publication of 12-week data from the Phase III, randomised double-blind, SELECT-PsA 1 study, earlier this year, McInnes, et al. now report the 56-week efficacy and safety data of upadacitinib 15 mg and 30 mg in patients with PsA and an inadequate response to non-biological therapy
Efficacy responses and inhibition of radiographic progression were maintained with upadacitinib 15 mg and 30 mg treatment over 56 weeks, with additional improvements in efficacy observed in patients who switched from placebo to upadacitinib at 24 weeks.
No new safety findings were observed with longer term exposure to upadacitinib